By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Nivalis Therapeutics (Formerly Known As N30 Pharma) 

Boulder  Colorado    U.S.A.
Phone: n/a Fax: n/a


Company News
Nivalis Therapeutics Announces Appointment Of Paul Sekhri To Its Board Of Directors 3/2/2016 8:07:14 AM
Nivalis Therapeutics Announces First Patient Dosed In Phase II Study Of N91115 For Treatment Of Cystic Fibrosis 12/1/2015 7:22:08 AM
Nivalis Therapeutics Announces Positive Phase Ib Results For N91115 In Patients With Cystic Fibrosis And Plans To Initiate Phase II Trial 10/8/2015 12:57:17 PM
Nivalis Therapeutics To Present At Two Upcoming Investor Conferences 9/4/2015 7:20:35 AM
Nivalis Therapeutics Reports Financial Results For The Second Quarter 2015 8/4/2015 8:12:23 AM
Nivalis Therapeutics IPO Nets $88M 6/23/2015 6:16:17 AM
Nivalis Therapeutics Set to Debut Tomorrow at $14 Per Share 6/17/2015 6:27:40 AM
Cystic Fibrosis Biotech Nivalis Therapeutics Files for $60 Million IPO 5/14/2015 6:31:42 AM
N30 Pharma Announces Name Change To Nivalis Therapeutics 2/24/2015 8:14:37 AM
N30 Pharma Appoints Jon Congleton As President And CEO 12/22/2014 8:24:19 AM